Literature DB >> 2256356

Papillary thyroid carcinoma: the new, age-related TNM classification system in a retrospective analysis of 199 patients.

S T Kukkonen1, R K Haapiainen, K O Franssila, A H Sivula.   

Abstract

The new, age-related TNM classification system of papillary thyroid carcinoma was applied in a retrospective analysis of 199 patients operated on during the 24-year period from 1956 through 1979 at the Second Department of Surgery, Helsinki University Central Hospital. According to the new staging system, 103 patients (under 45 years of age) and 96 T1 patients (45 years of age and older) were categorized into stage I. The incidence of carcinoma-positive cervical lymph nodes was highest among patients under 30 years of age at primary surgery. During the follow-up period of 6-29 years, cervical lymph node involvement was verified at reoperation in 20 patients (10%). Distant metastases (bone or lung) developed in 11 patients (5.5%). Thirty-one patients (16%) died from carcinoma. The prognostic value of stage grouping, in terms of metastatic tendency and cancer mortality, was clearly demonstrated in the present material, suggesting the suitability of this simplified, new, age-related staging system in clinical practice.

Entities:  

Mesh:

Year:  1990        PMID: 2256356     DOI: 10.1007/bf01670533

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  15 in total

1.  Papillary cancer of the thyroid; a review of 25 years of experience.

Authors:  E L FRAZELL; F W FOOTE
Journal:  Cancer       Date:  1958 Sep-Oct       Impact factor: 6.860

2.  Deaths due to differentiated thyroid cancer: a 46-year perspective.

Authors:  J K Harness; M K McLeod; N W Thompson; W C Noble; R E Burney
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

3.  Changing end results in patients with papillary carcinoma of the thyroid.

Authors:  G Crile
Journal:  Surg Gynecol Obstet       Date:  1971-03

Review 4.  Surgical strategy in thyroid carcinoma: a clinical review.

Authors:  S Lennquist
Journal:  Acta Chir Scand       Date:  1986-05

5.  Papillary thyroid carcinoma: the impact of therapy in 576 patients.

Authors:  E L Mazzaferri; R L Young; J E Oertel; W T Kemmerer; C P Page
Journal:  Medicine (Baltimore)       Date:  1977-05       Impact factor: 1.889

6.  Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma.

Authors:  B Cady; C E Sedgwick; W A Meissner; J R Bookwalter; V Romagosa; J Werber
Journal:  Ann Surg       Date:  1976-11       Impact factor: 12.969

7.  Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up.

Authors:  J Tennvall; A Biörklund; T Möller; J Ranstam; M Akerman
Journal:  Cancer       Date:  1986-04-01       Impact factor: 6.860

8.  Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases.

Authors:  N A Samaan; Y K Maheshwari; S Nader; C S Hill; P N Schultz; T P Haynie; R C Hickey; R L Clark; H Goepfert; M L Ibanez; C E Litton
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

9.  Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients.

Authors:  E L Mazzaferri; R L Young
Journal:  Am J Med       Date:  1981-03       Impact factor: 4.965

10.  Further evidence of the validity of risk group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi; M Silverman; M Wool
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

View more
  8 in total

Review 1.  Recurrent or persistent thyroid cancer of follicular cell origin.

Authors:  M Duren; Q Y Duh; A E Siperstein; O H Clark
Journal:  Curr Treat Options Oncol       Date:  2000-10

2.  Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours.

Authors:  M Miettinen; P Kärkkäinen
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

3.  Optimizing the treatment of AMES high-risk papillary thyroid carcinoma.

Authors:  Chung-Yau Lo; Wai-Fan Chan; King-Yin Lam; Koon-Yat Wan
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

4.  Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131)

Authors:  M Coburn; D Teates; H J Wanebo
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

Review 5.  The pros and cons of routine central compartment neck dissection for clinically nodal negative (cN0) papillary thyroid cancer.

Authors:  Ai Chen Chan; Brian Hung Hin Lang; Kai Pun Wong
Journal:  Gland Surg       Date:  2013-11

6.  Response to Treatment is Highly Predictable in cN0 Patients with Papillary Thyroid Carcinoma.

Authors:  Alexander Gorshtein; Carlos Benbassat; Eyal Robenshtok; Ilan Shimon; Dania Hirsch
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

7.  Resection of metastatic thyroid carcinomas to the liver and the kidney: report of a case.

Authors:  G E Tur; Y Asanuma; T Sato; H Kotanagi; M Sageshima; Z Yong-Jie; K Koyama
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

8.  The role of prophylactic central neck dissection in differentiated thyroid carcinoma: issues and controversies.

Authors:  Kai-Pun Wong; Brian Hung-Hin Lang
Journal:  J Oncol       Date:  2011-09-29       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.